Research Article

NLRP3 Inflammasome Polymorphism and Macrovascular Complications in Type 2 Diabetes Patients

Table 1

Patients characteristics.

All patients ()Macrovascular complications
()
Microvascular complications ()

Male genderc105 (58.0)29 (63.0)0.423d23 (67.6)0.206d
Age (years)64.0 (58.5–70.5)64.0 (58.8–72.3)0.49564.0 (58.0–75.3)0.251
Duration of T2D (years)11.0 (6.0–17.0)16.0 (7.0–23.5)0.00320.5 (11.0–27.0)0.000
HbA1c (%) [mmol/mol]6.9 (6.3–7.6) [52 (45–60)]6.7 (5.9–7.4) [50 (41–57)]0.1436.5 (5.8–7.7) [48 (40–61)]0.020
BMI (kg/m2)30.0 (28.0–33.3)30.0 (27.0–33.1)0.74129 (25.8–32.4)0.191
Blood pressure systolic (mmHg)135.0 (130.0–145.0)140.0 (128.8–150.5)0.257139.0 (119.3–149.0)0.759
Blood pressure diastolic (mmHg)80.0 (70.0–80.0)75.0 (65.8–80.0)0.01472.0 (63.0–80.0)0.000
Total cholesterol (mmol/L)4.2 (3.5–5.0)3.9 (3.1–4.5)0.0043.7 (2.9–4.7)0.002
LDL cholesterol (mmol/L)2.4 (1.9–3.1)2.3 (1.5–2.7)0.0472.0 (1.5–2.4)0.004
HDL cholesterol (mmol/L)1.1 (1.0–1.4)1.1 (0.9–1.3)0.0091.1 (0.9–1.4)0.323
TAG (mmol/L)1.6 (1.2–2.4)1.7 (1.1–2.2)0.5871.3 (0.9–2.1)0.046

Comparison between patients with and without macrovascular complications. bComparison between patients with and without microvascular complications.
Data are shown as median (25%–75%), except for c (%). values were calculated using Mann-Whitney test, except for dchi square test.